NAA Services for Anti-HCC-22-5

Diagnosis of gastric cancer in the early stage is a problem because of the lack of specific symptoms. The diagnostic potential of a natural autoantibody (NAA) panel provides a novel tool for the early detection of gastric cancer. As an industry leader in the field of disease diagnosis, Creative Biolabs is committed to providing the most comprehensive autoantibody services for our global clients. Having accumulated abundant experience in the successful completion of many NAA-related projects, Creative Biolabs provides anti-HCC-22-5 antibody services for the research of gastric cancer with the best quality and the most competitive prices.

Background of Anti-HCC-22-5 Antibody

Serological identification of antigens by recombinant expression cloning (SEREX) is a promising method used to analyze tumor-associated antigens (TAAs). HCC-22-5 has originally been found from an HCC cDNA library using autogenous serum by the SEREX approach. Studies revealed that both purified HCC-22-5 and HCC-22-5 fusion proteins had an immune response to serum antibodies of HCC. Anti-HCC-22-5 antibody is not found in sera of healthy individuals, but it is found in sera of patients with gastric cancer, along with other TAAs such as heat shock protein 70, HCC-22-5, peroxiredoxin VI, KM-HN-1, and p90. Some autoantibodies, such as anti-HCC-22-5, anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers.

Fig.1 Sensitivity of TAAs and a panel of six autoantibodies for detecting gastric cancer. (Hoshino, 2017)

The Role of Anti-HCC-22-5 in Gastric Cancer

Gastric cancer is the second leading cause of cancer death in the world, and effective diagnosis is extremely important for a good outcome. Serum tumor markers, such as CEA, CA19-9, and CA72-4 have limited sensitivity and specificity for gastric cancer screening. The humoral immune response against TAAs has generated already during premalignant stages. Thus, autoantibodies against TAAs have been suggested as biomarkers for early detection of gastric cancer. In fact, serum autoantibodies against HCC-22-5 are detectable in early-stage gastric cancer patients.

Fig.2 Gastric cancer disease. (Kumar, et al., 2013)

What We Can Do About NAA?

Equipped with our well-established platforms and experienced scientists, we can provide comprehensive NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. A wide spectrum of NAA products is available for your choice.

Autoantibodies against TAAs are very attractive biomarkers for the development of noninvasive serological tests for the early detection of gastric cancer because of their specificity and stability. Creative Biolabs provides a full range of high-affinity anti-HCC-22-5 marker autoantibody services for the diagnosis of gastric cancer. Our high-quality services will contribute greatly to the success of your project. Please contact us for more information if you are interested in our services.

References:

Hoshino, I.; et al. Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer science. 2017, 108(3): 308-315.
Kumar, R. K.; et al. Gastric carcinoma: a review on epidemiology, current surgical and chemotherapeutic options. Gastric Carcinoma-New Insights into Current Management. 2013, 12.

For Research Use Only | Not For Clinical Use

Related Services:

Products:

NAA Detection Kits

Resource:

Pathways

Applications:

Online Inquiry